Лимфома неходжкинская и беременность


Лимфома неходжкинская и беременность

Лимфома неходжкинская и беременность

Лимфома неходжкинская и беременность


Лучшие новости сайта

1. Байсоголов Г.В., Шишкиш И.П., Мед. Радиология, М., 1985, №2,С. 3537.

2. Гарин A.M. Вклад лекарственной терапии в повышение общей выживаемости онкологических больных. // Материалы IX Российского онкологического конгресса, М., 2005, С.22-24.

3. Демина Е.А., Ткачев С.И., Трофимова О.П. и др. // Материалы VIII Российского онкологического конгресса, М., 2004, С.121-125.

4. Демина Е.А. Лимфома Ходжкина.//РЛС, М.,2004,С. 605-614.

5. Демина Е.А. и соавт. Влияние беременности и родов на течение лимфомы Ходжкина. // Тезисы. Материалы 9-го Российского онкологического конгресса 22-25 ноября 2005г. М., стр. 128.

6. Демина Е.А., Махова Е.Е., Сусулева Н.А., Ильященко В.А. Возможности сохранения детородной функции у женщин с лимфомой Ходжкина.// РМЖ, 2005,№1, С.26-28.

7. Демина Е.А., Пылова И.В., Шмаков Р.Г., Перилова Е.Е. Поздние осложнения терапии больных лимфомой Ходжкина // Современная онкология, 2006, №1, С.36-43.

8. Демина Е.А., Перилова Е.Е., Шмаков Р.Г. //Использование комбинированных пероральных контрацептивов для профилактики повреждения функции яичников у больных лимфомой Ходжкина.//РЛС, 2004, С. 1352-1354.

9. Демина Е.А., Каверзнева М.М., Кондратьева Н.Ф., Агафонова В.А. Полихимиотерапия и комбинированное лечение больных лимфогранулематозом I — II стадий при неблагоприятном прогнозе. Тер. архив. 1990; Т.62. N7: 72-76.

10. Ю.Демина Е.А. Лимфогранулематоз.//Клиническая онкогематология, М.,2001, С. 314-336.11 .Демина Е.А.,Современная терапия первичных больных лимфомой

11. Ходжкина. Автореферат диссертации, на соискание ученой, степени-доктора медицинских наук., данные РОНЦ.

12. Демина Е.А. с соавт., Поздние осложнения терапии больных лимфомой Ходжкина//Современная онкология, М., 2006; №1, том8 С.36-43.

13. Игнашииа Е.В., Пивник А.В., Шилии Д.Е. и др.// Тер. Архив — 1997.-№11.С.71-73.

14. Игнашина Е.В:, Эндокринная регуляция репродуктивной-системы и ее сохранение у женщин с: болезнью Ходжкина в: процессе комбинированной терапии, Автореферат диссертации; на соискание ученой степени кандидата медицинских наук, М., .1-998:

15. ШИгнашина Е.В., Пивник А.В., Шилин Д.Е. и др. Профилактика репродуктивных нарушений, возникающих в процессе химиотерапии у женщин; детородного возраста, страдающих болезнью Ходжкина // Тер. Архив- 1998;-№7.-С.49-53.

16. Канаев С.В., Холин А.В. Современные подходы к лечению больных лимфогранулематозом. Вопросы онкологии: 1990; Т. 36. N8: 899-904.

17. Кваша А.Я; Что такое демографизм? М. 1985.:110.

18. Кулаков В.И. Репродуктивное здоровье населения России: медицинские, социальные и демографические проблемы. // Поликлиническая.гинекология;М;, 2005, С.263-273.

19. Лебедев В.И. Статистика и некоторые вопросы эпидемиологии злокачественных новообразований; лимфатической и кроветворной ткани. Вопросы онкологии. 1984; N4: 82-96.

20. Манухин И:Б., Тумилович Л.Г., Геворкян М.А.Физиология репродуктивной системы// Клинические лекции по гинекологическойэндокринологии. М., 2003,G.6-26.

21. Перелыитейн А.Э., Акушерсто и гинекология, 1958, №2,С.86-89.

22. Переводчикова Н.И. // Руководство по химиотерапии опухолевых заболеваний, М., 2005, С. 661.

23. Пробатова Н.А., Морфологические критерии диагностики злокачественных лимфом/ЛСлиническая онкогематология., М., С.301-314.

24. Терентьева Н.А. Диагностика злокачественных лимфом средостения. Автореферат диссертации на соискание ученой степени доктора медицинских наук. Горький. 1974.

25. ТупицынН.Н., Иммунодиагностика гемобластозов/ЯСлиническая онкогематология., М., С. 124-146.

26. Шехтман М.М., Руководство по экстрагенитальной патологии у беременных, М., 1999.

27. Шмаков Г.С., Комова Т.Д., Демина Е.А. Беременность и роды у женщин с лимфомой Ходжкина.//Материалы VI Российской онкологической конференции, М., 2002, С.59-60.

28. Фридкина Т.В., Франк Т. А. Прогностическое значение морфологической характеристики лимфогранулематоза. Мед. радиология. 1969. N11: 26-31.

29. Приказ Минздрава РФ от 28 декабря 1993г «Об утверждении перечня медицинских показаний для искусственного прерывания беременности», «Перечень медицинских показаний для прерывания беременности» (Приложение 2 к приказу Минздрава РФ от 28 декабря 1998г.

30. Abrahamsen A.F. Hannisdal Е., Nome О., et al. Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution. Ann Oncol. 1996; V.7, P. 145-150.

31. Ahmed Ebbiary NA, Lenton EA, Salt С et al. The significance of elevated basal follicle stimulating hormone in regularly menstruating infertilewomen. Hum Reprod 1994; V.9, P. 245-252.

32. Apperly JF, Reddy N. Mechanism and management of gonadal failure in recipients of high dose chemoradiotherapy. Blood Rev 1995; V.9, P. 93-116.

33. Anderson H., Crowther D., Deakin D.P., et al. A randomized study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10- year follou-up. Ann Oncol. 1991; V.2, P. 49.

34. Atay KM, McKanna JA, Weintraub AM et al. Prevention of chemotherapy-induced ovarian follicular loss in rats. Cancer Res 1985;V.45, P.3651-3656.

35. Aviles A. Diaz-Maqueo JC, Talavtra A, Guzman R, Garcia EL. Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol 1991;V.36, P.243-248.

36. Axtell L.M., Myers M.N., Thomas L.H. Prognostic indicators in Hodgkin's disease. Cancer. 1972; V.29, P. 1481-1488.

37. Bailliere's Clinical Yaematology. International Practice and Research. Hodgkin's Disease. Guest editor V. Diehi. London, Bailliere Tindall — 1996; Vol.9(Suppl3).

38. Baird DT, Webb R, Campbell BK et al. Long-term ovarian function in sheep after ovariectomy and transplantation of autografts stored at -196°C. Endocrinology 1999; V. 140, P.452-471.

39. Barniele MM. Chemotherapy and pregnancy. Semin Oncol Nurs 1992;V.8, P.124-132.43 .Barry RM, Diamond HD, Carver LF. Influence of pregnancy on the course of Hodgkin's disease. Am J Obstet Gynecol 1962; V.84, P. 445-454.

40. Bittl A, Beck E, Jager W, Wildt L. Untersuchungen zur Amenorrhoe unter adjuvanter CMF-Chemotherapie bei Mammakarzinom-Patientinnen. In: Eang N, Jager W, eds. Zytostatikabedingte Nebenwirkungen. Munchtn: Zuckschwerdt Verlag, 1993:P. 14-20.

41. Biskind OR, Kordan B, Biskind MS. Ovary transplanted to spleen in rats: the effect of unilateral castration, pregnancy and; subsequent castration. Cancer Res 1950; V. 10, P. 309-318:

42. Bjokholm H., Holm G., Mellstedt M., Johansson B. Prognostic factors in Hodgkin's disease: Analysis of histopathology, stage distribution; and results of therapy. Scand J Haematol. 1977; V. 19, P: 487-495.

43. Block E., Quantitative тофЬо1с^1еа1 invtstigations of the follicular system in women. Aeta Endocrinologica l951 ;V.8:, P.33.

44. Blumenfeld Z, Dann E, Avivi I, Epelbaum R. Fertility for Hodgkin's disease. Annals of Oncology 13 (Suppl. 1) 2002:P.138-147.

45. Blumenfeld Z, Avivi I Riter M, Rowe JM; Preservation of fertility and ovarian function and- minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Invest 1999;V.6, P.229-239.

46. Blumenfeld Z, Haim N. Preservation of gonadal damag during cytotoxic therapy. Ann Med 1997;V.29; P: 1323-1206.

47. Blumenfeld Z. ©reservation of fertily and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure:, the rol of inhibin-A and -B as markers. Mol Cell Endocrinol2002;V. 187, P.93-105.

48. Bymc J.,Fears TR., Gail M.N., et. al., Am. J Obstet Gynecol; 1992, Vol.166, P.7880.

49. Byrne J, Rasmussen SA, Steinhorn SC, et al: Genetic disease in off spring of long-term survivors of children and adolescent cancer. Am J Hum Genet 1998; V.62, P.45-52.iL

50. Cancer: Principles and Practice of Oncology. 4 Edition. Ed. by V.T.DeVita, S. Hellman, S.A. Roscnberg.-Philadelphia.- 1993.- V 2.

51. Cancer: Principles and Practic of Oncology.-5lh ed/Eds. by Marvin L., Rosenberg.-Philadelphia:-0000.-V 2;

52. Cancer: Principles and Practic of Oncology.-Vol 2:-6th ed/Eds. by V.T.DeVita, S. Hellman, S.A. Rosenberg.-Philadelphia: Lippincott-Raven Publishers. 2001.-chapter 45.

53. Carde P., Burgers J.M., Henry-Amar M., et al: Clinical stages I; and: II Hodgkin's disease: a specifically tailored therapy accoding to prognostic factors. J Clin Oncol. 1988; V.6, P. 239-252. 1

54. Cardc P., Burgers J.MlV., Hevry-Amar M. et al. J. clin. Oncol.-1988.-V0I.6.-P.239-247. ^

55. Callejo J, Salvador, C, Mirales A et ah Long-term ovarian function evaluation after autografting by implantation with fresh and frozenthawed human ovarian tissue. J Clin Endocrinol Metab 2001;V.86, P.4489-4494.

56. Campbell BK, Telfer EE,.Webb R. Baird DT. Ovarian autografts in sheep as a, model for studying folliculogenesis. Mol Cell Endocrinol 2000;V.163, P. 131-139;

57. СагЬоепе P.P., Kaplan H.S., Masshoff K., Tubiana M. Report of the

58. Commitee of Hodgkin's disease staging: Ann-Arbor classification. Cancer. 1971; V.31, P. 1860-1861.

59. Chakravarti A., Halloran S.L., Bale SJ., Tuker M.A. Etiological heterogeneity in Hodgkin's disease: HLA liked and unliked determinants of susceptibilety independent of histological concordance.Genet Epidemiol. 1986; V.3,P.407.

60. Chartman RM. Effect of cytotoxic therapy on sexuality and gonadal function. Semin Oncol 1982;V.9, P.84-135.

61. Chartman RM, Sutcliffe SB, Malpas JS. Cytotoxic induced ovarian falure in women with Hodgkin's disease. I. Hormonal function. JAMA 1979;V.242, P.13257-13281.

62. Chartman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood 1981;V.58, P. 849-851.

63. Condor Cardo С. O' Biten JP, Casals D, et al. Multidrug resistance gene (P glycoprotein) is experessed by endothelial cells at blood brain barrier sites. ProcNalt Acad Sei USA 1989;V.86, P.695-698.

64. Connoly R.R., Chistene B.W. A cohort study of cancer following infections mononucleosis. Cancer Res. 1974; V.34, P. 1172-1178.

65. Coriu D., Vasilica M., Gociu M., Colita D. Prognostic factor for early stage Hodgkin's disease. Haematologica. June 1999; Vol. 84: 157, abstr.0658.

66. Corlcta H, Corlela О, Сарр E, Edelweiss Ml. Subcutaneous autologous ovarian transplantation in Wistar rats maintains hormone secretion. Fertil Steril 1998; V.70, P. 16-19.

67. Cox D.R. Regression models and life-table (with discussion). J Royal Stat. 1972; V.34, P. 187-220.

68. Davis AB. Report of a case of Hodgkin's disease complicated by pregnancy. Bull Lying-in Hosp NY 1911;V.7, P. 151-158.

69. De Vita V., Serpick A. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Proc An Assoc Cancer Res. 1967;V. 8, P. 13.

70. De Vita V., Simon R., Hubbard S. et al. Curability of advanced Hodgkin's disease with chemotherapy: Long-term follow-up of MOPP treated patients, as NCI. Ann Intern Med. 1980; V.92, P. 587-595.

71. De Vita VT Jr, Simon RM, Hubbard SM et al. Curability of advanced Hodgkin's disease with chemotherapy. Ann Intern Med 1998;V.134, P.5136-51371

72. SO.Diehl V, Sieber Ml, Ruffer U. et ah ВЕАСОРР: An intensified chemotherapy regimen in advanced Hodgkin's disease. Ann of Oncol. 1997;. V.8, P. 143-148. "81 .Dichl V., Franclin J., Hansenclever D. Et ah, 1998; V.9.( suppl.5),P.68-71.

73. Doll DC, Ringerberg OS, Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol 1989;16:337-346.

74. IDonnez J, Dolmans MM; Demylle D, Jardoul P, Pirard C, Squifflet J, Martinez-Madrid B. Van Lange- ndonckt A. Live birth afte orthotopic transplantion of cryopreserved ovarian tissue. Eanse 2000;V.364:P. 14051410:

75. Flecher H., Tesch H:, Ann Oncol, 1998, V.9, P.39.

76. Fraumeni J. Family studies in Hodgkin's disease. Cancer Res. 1974;V. 34: P. 1164-1165.

77. Franklin J. And Diehl V. // Ann. Oncol. ,2002, 13 (Suppl 1), P. 98-101.

78. Fuller M.I., Hagemeister F.B. Diagnosis and manangement of Hodgkin's disease in the adult. Cancer. 1983; V.51: P;2469-2476.

79. Franchi-RezguI P, Rousselot P, Espie M; Brier. J;Pierre Marolleau J, Gisselbrecht C, Brice P. Fertility in young women afte chtmotherapy withalkylating agents for Hodgkin- and non-Hodgkin lymphomas. Hematol J., 2003;V.4:P.l 16-120.

80. Gause A., Roschansky V., Tsehierseh A. et al. Low serum interleukin-2 receptor levels correlated with a good prognosis in patients with Hodgkin's lymphoma. Ann Oncol. 1991; Vol. 2 (suppl 2), P. 43-48.

81. Gassmann W., Perenyl L., Schmits N., Pralle H. Prognostic factors in COPP-treated patients with Hodgkin's disease. Blut. 1982; V.44, P.339-342.

82. Gehan E.A. A generalised Wilcoxon test for the comparing arbitrarily singly-sensored samples. Biometrica. 1965; V.52, P.203-223.

83. Gelb AB, Van de Rijn M,Warnke RA, Kamel OW. Pregnancy-associated lymphomas. A clinicopathologic study. Cancer 1996;V.78,P.204-210 (see comments).

84. Gilbert R. Radiotherapy in Hodgkin's disease (malignant granulomatosis): Anatomic and clinical foundations: Governing principles: Results. Amer J Roentgenol. 1939; V.41,P. 198-241.

85. Gosden RG. Rutherford AJ, Norfolk DR. Debate: ovarian banking for cancer patients—transmission of malignant cells in ovarian grafts. Hum Reprod 1997; V. 12, P. 403.

86. Gosden RG, Baird DT, Wade JC et al. Restoration of fertility to oophorectomized sheep by ovarian autografts stored at -196°C. Hum Reprod 1994; V.9, P. 597-603.

87. Gradishar WJ, Schilsky RL. Ovarian function following radiation and chemotherapy for cancer. Semin Oncol 1989;V.16, P.425-436.

88. Gruss H.J., Brach M.A., Drexler H.G. et al. Interleukin-9 expressed by primary and cultured Hodgkin and Reed-Sternberg cells. Cancer Res. 1992; V.52,P. 1026-1031.

89. Glaser SL. Reproductive factors in Hodgkin's disease in women: a review. Am J Epidemiol 1994;V. 139, P.237-246.

90. Gunasena KR, Villines PM, Crilscr ES, Critser JK. Live births after autologous transplant of cryopreserved mouse ovaries. Hum Reprod 1997;1. V. 12, P. 101-106.

91. Hancock S., Hoppe R., Horning S. et al., Ann. Intrn. Med., V.109,P.183-189.

92. Henry-Amar M. Second cancer after the treatment of Hodgkin's disease: A report from the international database on Hodgkin's disease. Ann Oncol. 1992; Vol. 3 (suppl 4), P. 117-128.

93. Henry-Amar M., Aeppli D.M., Anderson J. et al. Workshop statistical report. In: Semin. Oncol., 1990, V. 17,P.758-768.

94. Henry-Amar M., Meerwaldt J.K., Carde P., eds. Treatment strategy in Hodgkin's disease. Colloque. INCERM no 196. London: INCERM/John Libbey Eurotext., 1990: V.17, P.l 17-128.

95. Herbst H., Niedobitek G., Kneba M. et al. High incidence of Epstein-Barr virus genomes in Hodgkin's disease. Am J Pathol. 1990; V.137, P.13-18.

96. Hodgkin's disease. Ed. By Mauch P.V., Armitage J.O., Diehl V. et al. -Philadelphia.-1999.

97. Hillier SG, Zeleznik AJ, Knazek RA, Ross GT. Hormonai reguiation of preovulatory follicle maturation in the rat. J Reprod Fertil 1980; V.60, P.219-229.

98. Hoppe R.T., Coleman C.N., Cox R.S., Rosenberg S.A., Kaplan H.S. The management of stage I-II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood. 1982; V.59, P.455.465. ' '

99. Horning S.J., Rosenberg S.A., Hoppe R.T. Brief chemotherapy- ' i

100. Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update . Ann Oncol. 1996;: Vol.7 (suppl 4), P. 105-108.113: Howel SJ, Shalet SM: Pharmacological protection of the gonads. Med1 Pediatr Oncol 1999; V.33, P.41-45.

101. Hudson- B.V., Mac Lennan K.A., Easterling M.S. The prognostic significance, of age in Hodgkin's disease, examination of the 1500 patients(BNL report N23). Clin Radiol. 1983; V.34, P.503-506.

102. Hummel M. Anagnostopoulos L, Dallnbach F. et ah EBV infection patterns in Hodgkin's disease and normal lymphoid,tissue: expression and: cellular localization of EBV gene product. British J I-laemotol. 1992; V.82, P.689-694.

103. Holmes GE, Holmes FF. Pregnancy outcome of patients treated? for Hodgkin's disease: a,controlled study. Cancer 1978; V.4T, P. 1317-1322.

104. Horning SJ, Hoppe RT, Kaplan NS, Rosenberg SA. Female reproductive potential: afte: treatment for Hodgkin's disease: N Eng J Med 1981; №7. V.304, P.1377-1382.

105. Jacobs C, Donaldson SS, Rosenbtrg SA, Kaplan HS. Magament of the pregnant patient with Hodgkin's disease. Ann lntern Med 1981 ;V.95, P:669-675.

106. Janov A.J;, Anderson J., Cella D.F., et al., Cance 1992, V.70, P.688.

107. Jarrett R.F., Amstrong А.А., Alexander F.E. Epstein-Barr virus and the epidimiology of Hodgkin's disease. Ann Oncol. 1996; Vol. 7 (suppl 4): P.5-10.

108. Jerusalem G., Beguin Y., Fassotte M.F. et al // Ann. Of Oncol. 2003, Y.14, P.123-130.

109. Jeffeiy G.M. et al. A risk factor for relapse in Hodgkin's disease female gender? Haematol Oncol. 1989; Vol.7, N5: P.345-353.

110. Johnson DH, Lind R, Hainsworth JD et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on post-therapy fertility in male patients with lymphoma: preliminary observation. Blood 1985; V.65, P.832-836.

111. Jucker M., Abts H., Li V. et al. Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. Blood. 1991; V.77, P. 2413.

112. Kaplan H.S., Meior P. Nouparemetrie estimation from incomplete observations. J Am Stat Assos. 1958; V.53, P. 457-481.

113. Kaplan H.S. Hodgkin's disease, 2nd ed. Cambridge Harvard University Press. 1980; P.588-597.

114. Keller A.R., Kaplan H.S., Lukes R.J. Correlation of histopatology with other prognostic indicators in Hodgkin's disease. Cancer. 1968; V.22, P. 287-299.

115. Kim SS, Battaglia DE, Soules MR. The future of ovarian cryopre-servation and transplantation: fertility and beyond. Fertil Steril 2001; V.75, P.1049-1056.

116. Ontario, Canada, September 25-30; 1999: Ferrtil Steril 1999;72(Suppl):SI (Abstr 003).

117. Kreuser ED, Xirus N, Hetzel WD, Himpel A. Reproductive and' endocrine gonadal caracity in patients, treated with OOPP chemotherapy of Hodgkin's disease. J Cancer Res Clin Oncol 1987; V. 134, P.260-266.

118. Kuentz M;, Reyes F., Brun В., Bierling P. Eraly response to chemotherapy as prognostic factor in Hodgkin's disease: Cancer. 1983; V.52, P. 780-785.

119. Lee C.K., Bloomfield E.D., Goldman A.J:, Levitt S.II. Prognostic significance of mediastinal involment in Hodgkin's disease treated; with, curative radiotherapy. Cancer. 1980; V.46, P.2403-2409.

120. Lister T.A., Crowther D., Sutchliffe S.B. et al. J. Clin. Oncol.-1989.-Vol.7.-P. 1630-1631.

121. Leslie N.T., Mauch P.M., Hellman S. Stage IA to JIB supradiaphragmatic Hodgkin's disease: long-term survival and relapse, frequency. Cancer. 1985; V.55, P. 2072-2078.

122. Loeffler M., Phreundschuh M. Prognostic risk factors in advanced Hodgkin's lymphoma. Blut. 1988; V.56, Pi 273-281.

123. Lukes R.J., Craver L.F., Hall T.S. et al: Cancer Res.-1966.-Voi:26.-P.311.

124. Lukes P.J., Butler J.J., Hicks E.D. Natural history of Hodgkin's disease as related to its patholodic picture. Cancer. 1966; V.19, P. 317-344.

125. Mack T.M., Cozen W., Shibata D.K. et al. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med. 1995; V.332, P. 413418.

126. Magrath I. Limiting therapy for limited childhrood non- Hodgkin's lymphoma. N Engl J Med 1997;V.337, P. 1374-1376.

127. Mattle V, Behringer K, Engert A,Wildt L. Femal fertility afte cytotocxic therapy-protection of ovarian function during chemotherapy of malignant and non-malignant diseases. Eur J Haematol 2005: 75(Suppl.66): P.77-82.

128. Mauch P., Goodman R., Hellman S. The significance of mediastinal involment in early stage Hodgkin's disease. Cancer. 1978; V.42, P. 10391045.

129. Mauch P., Ng A., Aleman В et al.: Europ. J. of Haematol. 2005, v 75, supl. 66, P. 68-76.

130. Meirow D, Epstein M, Lewis H et al. Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Human Reprod 2001; V.16, P. 632-637.

131. Miller R.W., Beebe G.W. Infectious mononucleosis and the emperical risk of cancer. J Natl Cancer Inst. 1973; V.50, P. 315-321.

132. Muller U, Stahel RA. Gonadal function after MACOP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin lymphoma. Ann Oncol 1993;V.4, P.399-402.

133. Munoz N., Davidson R.J., Witthoff B. et al. Infectious mononucleosis and Hodgkin's disease. Int J Cancer. 1978; V.22, P. 10-13.

134. Myers SE, Schilsky RL. Prospects for fertility afte cancer chemotherapy. Semin Oncol 1992;V.l9, P.597-604.

135. Newton II, Aubard Y, Sharma V ct al. The low temperature storage and grafting of human ovarian tissue: into SCID mice: Hum Reprod 1996; V. 11, P. 1487-1491.

136. Oktay K, Bujuk E, Veeck L, Zaninovic N, Xu K, Takeuchi T, Opsahl M, Rosenwaks Z. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; V.363, P.837-840:

137. Oktay K, Karlikaya G; Ovarian function; after transplantation of frozen, banked autologous ovarian tissue letter. N Engl J Med 2000; V.342, P. 1919:

138. Oktay К, Kan MT, Rosenwaks Z. Recent progress in oocyte tissue cryopreservation and trasplantation: Curr Opin Obstet Gynecol 2001;V. 13, P.263-268.

139. Oktay К, Newton H, Gosden RC. Transplantation of cryopreserved human ovarian tissue results in follicle growth initiation in SCID mice. Fertil Steril 2000;V.73, P.599-603.

140. Palacios Costa N, Chavanne FC, Zebel Fernancde D. An de atenio. Buenos Aires: 1945: P. 127.

141. Parrot DMV. The fertility of mice with orthopic ovarian grafts derived from frozen tissue. J Reprod Fertil 1954;V.l, P.230-241.

142. Peters M.V. A study of survival in Hodgkin's disease treated radiologically. Amer J Roentgenol. 1950; V.63, P. 299-311.

143. Pavlovsky S., Maschio M., Santarelli M.T. et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst. 1988; V.80, P. 1466-1473.

144. Posada MN, Kolp L, Garcia JE. Fertility options for female cancer patients: facts and fiction. Fertil Steril 2001; V.75, P. 647-653.

145. Preti A., Hagemeister F.B., Mc Laughlin P. et al. Hodgkin's disease with a mediastinal mass greater then 10 cm: results of four different treatment approaches. Ann Oncol. 1994; V.5, P. 97-100.

146. Radford JA, Shalet SM, Lieberman В A. Fertility after treatment for cancer. Br Med J 1999;V.319, P.935-936.

147. Raris D., Diamond H., Craver L. Familial Hodgkin's disease. Its significance and implication. Ann Intern Med. 1968; V.l21, P. 67-70.

148. Rivkees SA, Crawford JD. The relationship of gonadal damag to chemotherapy. JAMA 1998;V.259, P.2137-2135.

149. Robertson S.J., Lowman J.T,, Gutterman S. et al- Familial Hodgkin's disease: A clinical and laboratory, investidation. Cancer. 1987; V.59, P. 1314-1319:

150. Rosdalh N., Larsen S.O. Clcmmensen J. Hodgkin's disease in patients with previous mononucleosis. 30: years experience. Br Med J. 1974;V. 2, P. 253-256.

151. Say G., Lee Y-T.N. et al. Prognostic factors in Hodgkin's disease. J Surg Oncol. 1975; V.7, P. 255-267.

152. Sankila R, Olsen JH; Anderson: H, et alt Risk of cancer among offspring of childhood cancer survivors. N Engl J Med 1998;V.338, P.T339-1344.

153. Shaw JM, Dawson KJ, Trounson AO. A critical evaluation of ovarian tissue cryopreservation and grafting as a strategy for: preserving the human lemal germline. Reprod Med Rev 1997;V.6, P. 163-183.

154. Shaw JM, Bowels J, Koopman P.' Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to the graft recipient. Hum Reprod 1996; V.l 1, P. 1668-1673.

155. Stewart H.L., Monto R.W. Hodgkin's disease and pregnancy. Am de Obstet Gynecol 1952; V.63, P. 507-558.

156. Tesch H:, Engert A., Lathan В., Loffler M; et al. Therapy of Hodgkin's disease: Oncologic. 1993; V.16, P. 407-415.

157. Tucker M.A., Coleman C.N., Cox R.S: et al: Risk of second cancer after treatment for Hodgkin's disease: N Engl J Med., 1988; V.318, P. 7681. .

158. Tubiana M:, Henry-Amar M., Wan der Werf-Messing B. et al. A multivariate analysis of prognostic factors in early stage Hodgkin's disease. Int J Radiol Oncol Biol Phys. 1985; V. 11, P. 23-30;

159. Waxman JH- AhmedlR, Smith D et al. Failure to preserve fertily in patients with Hodgkin's disease: Cancer Chemother Pharmacol 1987;V. 19, P. 159-162.

160. Wedelin C., Bjokholm M., Biberfild P: Prodnostic factors in Hodgkin's disease: with, special reference to age. Cancer. 1984; V.53, P. 1203-1208;

161. Weiss L.M., Movahed L.A., Warnke R.A., Sklar J. Detection of \

162. Epstein-Barr viral genomes in Reed-Stenberg cells of Hodgkin's disease: N Engl J Med. 1989; V.320, P. 502-506.

163. Yahalom J; Treatment option, for Hodgkin's disease during pregnancy. Leuk Lymphoma 1990;V.2:, P. 151-161.


Источник: http://www.dissercat.com/content/reproduktivnaya-funktsiya-u-zhenshchin-bolnykh-limfomoi-khodzhkina-vliyanie-beremennosti-i-r


Лимфома неходжкинская и беременность фото


Лимфома неходжкинская и беременность

Лимфома неходжкинская и беременность

Лимфома неходжкинская и беременность

Лимфома неходжкинская и беременность

Лимфома неходжкинская и беременность

Лимфома неходжкинская и беременность

Лимфома неходжкинская и беременность

Читать: